Comments on: Switch Therapeutics appoints David M. Holtzman, M.D. to its Scientific Advisory Board and announces its first development candidate, CASi-APOE, a liver-sparing APOE RNAi therapy

Comments on: Switch Therapeutics appoints David M. Holtzman, M.D. to its Scientific Advisory Board and announces its first development candidate, CASi-APOE, a liver-sparing APOE RNAi therapy https://www.switchthera.com/news/switch-therapeutics-appoints-david-m-holtzman-m-d-to-its-scientific-advisory-board-and-announces-its-first-development-candidate-casi-apoe-a-liver-sparing-apoe-rnai-therapy/ Revolutionizing RNAi Therapies Tue, 03 Dec 2024 01:43:20 +0000 hourly 1 https://wordpress.org/?v=7.1.4